Iloprost, ein stabiles Prostacyclinderivat, bei arterieller Verschlußkrankheit im Stadium IV: Eine placebo-kontrollierte Multizenterstudie

The effectiveness of iloprost, a prostacyclin derivative, was assessed in a placebo-controlled multicentre trial on 101 patients with chronic arterial disease, stage IV. All patients were on a basic local treatment, 53 randomly being assigned to the iloprost group, 48 to the placebo one. Both groups received identical saline infusions, one with the other without iloprost. Infusions were given on 28 consecutive days, iloprost being added at a...